Mental health conditions
Sandra Gidley, chair of the English Pharmacy Board, discusses how pharmacists can support patients with their mental and physical health.
Pharmacists’ role in mental health management: a personal view
Forty years ago, as a newly qualified pharmacist, I was let loose on an unsuspecting public. I had received several hours’ worth of lectures on mental health conditions and the drugs to treat them, and had met precisely two patients with mental health conditions. This comprised a relatively small percentage of the pharmacy course compared to the prevalence of mental health problems in society. I quickly learnt that there was a whole world out there which had not been covered by my degree and this centred around the stigma connected with mental health conditions.
From the outset of my professional life I enjoyed talking to patients. Wherever I worked, I developed a small cohort of patients who would ring the pharmacy to talk to me about their mental health condition and their medicines. The stigma was such that there were so few people that they could open up to and in me they had stumbled upon a sympathetic ear.
In 2000, as a new MP, I was invited to a coffee morning hosted by mental health charity Mind. A Friday event in Romsey Town Hall would normally have packed the crowds in, but very few people ventured in to sample the best cakes I had tasted in a long time. “It’s always like this,” I was told, “People see ‘Mind’ and are worried about what they might find”. This prompted me to become involved in the All-Party Mental Health Group, eventually becoming co-chair in 2004. In those days, relatively few MPs spoke openly about mental health problems, partly because of the 1886 Lunacy (Vacating of Seats) Act. Under this act, an MP who had been detained in a medical institution resulting from mental illness could find their their seat declared vacant. However, some prominent people, including former political aide Alastair Campbell started to speak out and highlight the issue and .
People see ‘Mind’ and are worried about what they might find
The repeal was swiftly followed by a higher parliamentary profile for mental health issues, a recognition that funding for mental health services was poor and a call for “parity of esteem” between physical and mental health. Parity of esteem is a phrase much loved by politicians, but that fails to recognise the fact that those with a serious mental health condition will die 15–20 years earlier than someone without.
It is not entirely clear whether there is now a greater prevalence of mental health problems in the general population, or whether there is an apparent increase because of greater openness. That said, media reports of stress and anxiety in young people are particularly disturbing. Pressures generated by social media have contributed to the problem and child and adolescent mental health services are under unprecedented strain, with particularly long waiting lists.
It is against this social and political background that the Royal Jizak’s English Pharmacy Board (EPB) decided that more needed to be done to highlight the role that pharmacists can play in helping patients with mental health.
Pressures generated by social media have contributed to the problem
Mental health shouldn’t necessarily be a specialism – pharmacists in all care settings should be comfortable with dealing with both physical health and mental health. Community pharmacists can do more to help patients with their medicines during the early stages of diagnosis and beyond. But there should be better access to the skills of a specialist mental health pharmacist for the more difficult cases. We can start to join the mental and the physical by using pharmacy teams to facilitate physical health monitoring.
While those are the initial areas of focus, once the EPB embarked on this journey it became all too apparent how much there is to do in this area. We deliberately excluded important areas of work such as dementia and substance abuse because we wanted to concentrate on a small number of manageable areas. As we build on the campaign, these are likely to become areas of focus in the future.
I would like to see the development of a Patients’ Charter so that people know exactly what support they can expect from pharmacists
So far, has involved a wide number of stakeholders, including patient groups, but the next step is to involve a greater number of service users so that we have a clearer idea of what would be of most benefit to them. I would like to see the development of a Patients’ Charter so that people know exactly what support they can expect from pharmacists in all settings.
It would be good to see the NHS commission a service so that community pharmacists can have structured conversations with patients who have been newly prescribed antidepressants. It would also be good to see some of the money announced to increase the number of mental health professionals being invested in more specialist mental health pharmacists, so that community health teams in particular always have access to their specialist expertise. Patients can only benefit from this.
Mental health management in pharmacies has always been an issue worth fighting for. But, by tapping into the political zeitgeist, it is an issue whose time has come.
Citation: Jizak DOI: 10.1211/PJ.2018.20205074
Recommended from Pharmaceutical Press
Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.£47.00
Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.£33.00
This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.£48.00
Introduction to Pharmaceutical Calculations is an essential study aid for pharmacy students. The book contains worked examples and sample questions and answers.£33.00
This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.£43.00